An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
Status:
Completed
Trial end date:
2019-05-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly
and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of
placebo in participants with chronic migraine (CM) or episodic migraine (EM) who have
responded inadequately to 2 to 4 classes of prior preventive treatments.
Approximately equal numbers of participants from each subgroup (CM and EM) are randomized in
blinded-fashion 1:1:1 into one of 3 treatments for the subgroup - 2 active treatments and 1
placebo treatment- consisting of monthly injections for 3 months (up to Week 12). Then all
participants continue into an open-label extension of 3 months (up to Week 24) during which
everyone is administered sc injections of fremanezumab.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.